Longevity Patent Family

MACROCYCLIC BLOCKERS FOR USE IN THE REDUCTION OF PERIPHERAL SIDE EFFECTS DUE TO EVEROLIMUS THERAPY

Source-linked patent metadata for MACROCYCLIC BLOCKERS FOR USE IN THE REDUCTION OF PERIPHERAL SIDE EFFECTS DUE TO EVEROLIMUS THERAPY, including priority, record stage and longevity-topic connections.

Patent-family snapshot

Application publication visible

Family grouping brings related publications for the same invention together, instead of counting every national filing as a separate technology.

Representative publication
WO2026060005A1
Earliest priority
September 10, 2024
Latest publication
March 19, 2026
Family publications
1
Patent offices
1
Patent-to-Evidence Translation Map

What is happening in the same scientific field?

These connections share a longevity topic with this patent record. They do not prove that the listed evidence, trials, funders, or universities validate, finance, own, or support this invention.

Organizations

Organizations named in this family

MONTARA THERAPEUTICS, INC.ApplicantMONTARA THERAPEUTICS INC [US]Applicant
Longevity context

Topics connected by metadata

Rapamycin88% metadata match
Knowledge connections

What this family cites

Earlier patent references
0
Scientific and other non-patent references
0
Priority dates represented
2

References show which earlier documents the patent record points to. They do not validate the invention or prove that cited research supports its claims.

Technical classification

How the patent office classifies this invention

No patent classification is available in the retained record.

Verify in the original patent source →